"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 5 | 3 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 4 | 1 | 5 |
| 2011 | 3 | 2 | 5 |
| 2012 | 5 | 6 | 11 |
| 2013 | 4 | 3 | 7 |
| 2014 | 6 | 3 | 9 |
| 2015 | 9 | 8 | 17 |
| 2016 | 8 | 7 | 15 |
| 2017 | 9 | 7 | 16 |
| 2018 | 14 | 6 | 20 |
| 2019 | 7 | 6 | 13 |
| 2020 | 8 | 10 | 18 |
| 2021 | 7 | 7 | 14 |
| 2022 | 0 | 13 | 13 |
| 2023 | 1 | 12 | 13 |
| 2024 | 5 | 13 | 18 |
| 2025 | 10 | 9 | 19 |
| 2026 | 4 | 7 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities. Am J Hematol. 2026 Nov; 101(11):2799-2811.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab. Clin Infect Dis. 2026 08 24; 82(Suppl 3):i18-i23.
-
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstr?m macroglobulinemia. Blood. 2026 05 14; 147(20):2298-2314.
-
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstr?m macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May; 13(5):e284-e296.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis. Am J Kidney Dis. 2026 Mar; 87(3):313-323.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
-
Clinical implications of combination proton pump inhibitor and triple therapies in patients with atrial fibrillation following percutaneous intervention: a guide for clinicians. Expert Rev Cardiovasc Ther. 2024 Sep; 22(9):483-491.